Filing Flows › Intellia Therapeutics (NTLA) › Guidance & outlook
Intellia Therapeutics (NTLA) guidance and outlook
Intellia Therapeutics' 10-Q filed Nov 5, 2026 makes 14 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- the issuance or enforcement of, and compliance with, regulatory requirements and guidance regarding nonclinical and clinical studies relevant to genome editing and our product candidates;
- our ability to comply with the obligations and meet the targets set forth under our credit facility;
- With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.
- Our research efforts focus on pursuing additional targets within the liver and expanding our targets and delivery technology for diseases outside the liver.
- On November 4, we announced that we completed enrollment in our MAGNITUDE-2 Phase 3 clinical trial in hereditary ATTR amyloidosis with polyneuropathy (“ATTRv-PN”) during the third quarter, exceeding our targeted randomization of 60 patients.
- As we engage with the FDA regarding this finding, we will provide HLA genotyping results for patients who are enrolled or entering screening in the ongoing nex-z Phase 3 trials.
- In September 2026, we entered into the Credit Agreement described in Note 10, “Debt,” in the notes to condensed consolidated financial statements, which provides Intellia with a five-year senior secured credit facility of up to $400 million. $75 million was drawn upon closing (the “Initial Term Loan”), several potential delayed draw term loans amounting to $225 million are available if certain targets are met and…
- Our primary uses of capital are, and we expect will continue to be, research and development, research materials and contracted services, clinical trial costs, compensation and related expenses, laboratory and office facilities, research supplies, legal and regulatory expenses, patent prosecution filing and maintenance costs for our licensed intellectual property, commercial launch capabilities, milestone and…
- During 2026, we expect our research and development expenses to decrease compared to prior periods as we focus resources on high value programs within our pipeline, such as lonvo-z and nex-z, to ensure efficient execution, achieve near-term clinical milestones, and prepare for commercial launch.
- We expect the decrease in research and development expenses to be mostly offset by increased expenses in 2026 related to our ongoing buildout of a commercial infrastructure.
- Until such time as we can generate substantial product revenues, if ever, we expect to fund our ongoing cash needs through financings and collaboration arrangements.
- Except for these sources of funding, we will not have any committed external source of liquidity.
Intellia Therapeutics' latest quarter
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.
Questions
What does Intellia Therapeutics expect?
the issuance or enforcement of, and compliance with, regulatory requirements and guidance regarding nonclinical and clinical studies relevant to genome editing and our product candidates; our ability to comply with the obligations and meet the targets set forth under our credit facility; With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.